Our data also suggest that in AIPC condition, Menin activates the PI3K/AKT alternative oncogenic pathway and promotes treatment resistance through activation of the oncogene MET, which was reported as a key participant in resistance mechanisms for targeted therapies in multiple types of cancers [46]. This evidence concerns the gene MET and cancer.